LIVZON PHARMA (01513) announced that the company and its subsidiaries plan to utilize idle自有资金 not exceeding 2.5 billion yuan to purchase委托理财产品. Within the authorized quota, the funds can be used on a rolling basis. The total investment amount used to purchase financial products at any given time, including amounts reinvested from the proceeds of prior investments, shall not exceed the stated quota.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments